Literature DB >> 14605068

Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma.

John G Edwards1, Daniel E B Swinson, J Louise Jones, Salli Muller, David A Waller, Kenneth J O'Byrne.   

Abstract

OBJECTIVES: Malignant mesothelioma (MM) is a fatal tumor of increasing incidence related to asbestos exposure. Microscopic tumor necrosis (TN) is a poor prognostic factor in solid tumors, but it has not been characterized in MM. We wished to evaluate the incidence of TN in MM and its correlations with clinicopathologic factors, angiogenesis, and survival.
METHODS: TN was graded in 171 routine formalin-fixed, paraffin-embedded hematoxylin-eosin-stained tumor sections by two independent observers. Angiogenesis was assessed by the microvessel count (MVC) of CD34 immunostained sections. TN was correlated with survival by Kaplan-Meier and log-rank analysis, and stepwise, multivariate Cox models were used to compare TN with angiogenesis and established prognostic factors and prognostic scoring systems.
RESULTS: TN was identified in 39 cases (22.8%) and correlated with low hemoglobin (p = 0.01), thrombocytosis (p = 0.04), and high MVC (p = 0.02). TN was a poor prognostic factor in univariate analysis (p = 0.008). Patients with TN had a median survival of 5.3 months vs 8.3 months in negative cases. Independent indicators of poor prognosis in multivariate analysis were nonepithelioid cell type (p = 0.0001), performance status > 0 (p = 0.007), and increasing MVC (p = 0.004) but not TN. TN contributed independently to the European Organisation for Research and Treatment of Cancer (EORTC) [p = 0.03] and to the Cancer and Leukemia Group B (CALGB) [p = 0.03] prognostic groups in respective multivariate Cox analyses.
CONCLUSIONS: TN correlates with angiogenesis and is a poor prognostic factor in MM. TN contributes to the EORTC and CALGB prognostic scoring systems.

Entities:  

Mesh:

Year:  2003        PMID: 14605068     DOI: 10.1378/chest.124.5.1916

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  23 in total

1.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

2.  Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?

Authors:  Pedro Góes; Bruno Fernandes Oliveira Santos; Fernando Seiji Suzuki; Débora Salles; João Noberto Stávale; Sérgio Cavalheiro; Manoel Antônio de Paiva Neto
Journal:  J Neurooncol       Date:  2017-12-21       Impact factor: 4.130

3.  Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.

Authors:  Gencay Hatiboglu; Markus Hohenfellner; Aysenur Arslan; Boris Hadaschik; Dogu Teber; Jan Philipp Radtke; Peter Hallscheidt; Yanis Tolstov; Wilfried Roth; Carsten Grüllich; Johannes Huesing; Stefan Duensing; Sascha Pahernik
Journal:  Langenbecks Arch Surg       Date:  2016-12-23       Impact factor: 3.445

Review 4.  The recent progress of the mechanism and regulation of tumor necrosis in colorectal cancer.

Authors:  Xi Zhang; Lirong Chen
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-21       Impact factor: 4.553

5.  Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy.

Authors:  Terence C Chua; Peng Yao; Javed Akther; David L Morris
Journal:  Pathol Oncol Res       Date:  2009-10-01       Impact factor: 3.201

Review 6.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors.

Authors:  Liat Goldshaid; Efrat Rubinstein; Alexander Brandis; Dadi Segal; Noa Leshem; Ori Brenner; Vyacheslav Kalchenko; Doron Eren; Tamar Yecheskel; Yoseph Salitra; Yoram Salomon; Avigdor Scherz
Journal:  Breast Cancer Res       Date:  2010-05-24       Impact factor: 6.466

8.  Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.

Authors:  E Giovannetti; P A Zucali; Y G Assaraf; L G Leon; K Smid; C Alecci; F Giancola; A Destro; L Gianoncelli; E Lorenzi; M Roncalli; A Santoro; G J Peters
Journal:  Br J Cancer       Date:  2011-10-04       Impact factor: 7.640

9.  Tumor necrosis: A synergistic consequence of metabolic stress and inflammation.

Authors:  Patricia P Yee; Wei Li
Journal:  Bioessays       Date:  2021-05-16       Impact factor: 4.653

10.  Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis.

Authors:  Daniele Martarelli; Alfonso Catalano; Antonio Procopio; Sara Orecchia; Roberta Libener; Giorgio Santoni
Journal:  BMC Cancer       Date:  2006-05-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.